Table 1 The baseline demographic and clinic features of 60 RA patients
|  | RA patients (n = 60) | OA patients (n = 20) | Healthy controls (n = 20) |
|---|---|---|---|
Age (mean ± SD) | 58 (47.3–63) | 56.4 (50.6–65) | 51.2 (44.1–58.2) |
Female (%) | 48 (80.0) | 16 (80%) | 16 (80%) |
Disease duration (years) (median, min–max) | 6.3 (2.0–12.8) | – | – |
RF positive (%) | 37 (61.7) | – | – |
Anti-CCP antibody positive (%) | 53 (88.3) | – | – |
TJC (median, min–max) | 3 (1–10) | – | – |
SJC (median, min–max) | 1 (0–3) | – | – |
PGA (0–100 mm) (median, min–max) | 40.0 (20.0–60.0) | – | – |
EGA (0–100 mm) (median, min–max) | 40.0 (20.0–60.0) | – | – |
HAQ-DI (0–3) (median, min–max) | 0.38 (0.11–1.04) | – | – |
ESR (mm/h) (median, min–max) | 18.5 (9–39) | – | – |
CRP (mg/L) (median, min–max) | 5.99 (2.44–15.23) | – | – |
DAS28-ESR (mean ± SD) | 3.6 (2.6–5.4) | – | – |
DAS28-CRP (mean ± SD) | 3.2 (2.6–5.1) | – | – |
SDAI (median, min–max) | 11.9 (6.6–29.2) | – | – |
CDAI (median, min–max) | 11.5 (6–27) | – | – |
Medication history (DMARDs) | |||
Metrotrexate | 44 (73.3%) | – | – |
Leflunomide | 27 (45%) | – | – |
Hydroxychloroquine | 25 (41.7%) | – | – |
Glucocorticoid | 16 (26.7%) | – | – |
Iguratimod | 14 (23.3%) | – | – |
Sulfasalazine | 6 (10%) | – | – |
Tripterygium wilfordii | 9 (15%) | – | – |